AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$SERA

Lindgardt Zhenya sold $40K of SERA

Lindgardt Zhenya (Chief Executive Officer) sold 20,139 shares of SERA PROGNOSTICS, INC. (SERA) at $2.00 on 2026-09-08.

Original reporting
SEC EDGAR · Lindgardt Zhenya
Published Sep 9, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SERA
Neutral
high confidence
Mentioned
$SERA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SERANeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to affect investor sentiment significantly.

02

Market read

Limited relevance; the filing provides a new data point but is too small to drive trading decisions.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 4/10Timing: today

Background

Form 4 filings disclose insider transactions; small sales are common and often routine.

Company-level read

Ticker impact

$SERANeutralHigh confidence
Context

CEO Lindgardt Zhenya sold 20,139 shares for $40,278 in a Form 4 filing.

Expected impact

little to no immediate price movement

Evidence & confidence

The transaction represents less than 5% of insider holdings and is under $50k, unlikely to move the market.

Market effects

Sector

No material impact on the biotech sector.

Regional

No regional effect.

Global

Not relevant globally.

Counterpoint

What could challenge this read

The sell could be a routine liquidity move, not a signal of trouble.

Key entities

  • person
    Lindgardt Zhenya

    Chief Executive Officer of Sera Prognostics, Inc.

  • company
    Sera Prognostics, Inc.

    Biotech company listed on Nasdaq under ticker SERA.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SERA insider trading history →

Related articles

$SERAMed

SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS Company Drives Significant Increases in Test Volume and Ordering Providers with Florida Becoming Second Medicaid State Covering Test • PreTRM® test volume increases 54% sequentially and approximately five-

SEC EDGAR 8-K
$SERAMed

Sera (SERA) Q2 2026 Earnings Call Transcript

Sera Prognostics (SERA) reported Q2 2026 revenue of $30,000, up from $17,000 last year, with a net loss of $9.1 million. The company exceeded its payer engagement goal, reaching over 20 states, and launched four commercial partnership programs. Clinical data showed a 22% reduction in NICU admissions and a 30% reduction in neonatal morbidity among first-time mothers. Management expects cash to fund operations through 2029.

fool.com
$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Sera Prognostics (Nasdaq: SERA) reported Q2 2026 revenue of $30,000 versus $17,000 in Q2 2025, with operating expenses of $10.0 million and a net loss of $9.1 million. The company said Illinois Medicaid coverage for PreTRM proteomic tests expanded, it launched a fourth payer partnership program, and PRIME trial data showed reduced NICU admissions in first-time mothers. Cash was about $80.3 million.

prnewswire.com
$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Salt Lake City – August 12, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information t

SEC EDGAR 8-K